Secukinumab-induced paradoxical hidradenitis suppurativa successfully treated with adalimumab

Int J Dermatol. 2022 Feb;61(2):e79-e80. doi: 10.1111/ijd.15730. Epub 2021 Jul 13.

Authors

Graziella Babino¹, Ilenia D'Ambra¹, Elisabetta Fulgione¹, Roberto Alfano², Pasquale Verolino³, Giuseppe Argenziano¹

Affiliations

¹ Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
² Department of Anesthesiology, Surgery and Emergency, University of Campania "Luigi Vanvitelli", Naples, Italy.
³ Plastic Surgery Unit, Multidisciplinary, Department of Medical-Surgical and Dental Specialties, University of Campania "Luigi Vanvitelli", Naples, Italy.

PMID: 34258759
DOI: 10.1111/ijd.15730

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adalimumab / therapeutic use*
Antibodies, Monoclonal, Humanized / adverse effects*
Hidradenitis Suppurativa* / chemically induced
Hidradenitis Suppurativa* / drug therapy
Humans

Substances

Antibodies, Monoclonal, Humanized
secukinumab
Adalimumab